Cargando…

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis

In recent years, advances in the treatment and management of patients with systemic lupus erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus nephritis (LN) still represents a major life-threatening complication of the disease. Belimumab (BEL), a fully human m...

Descripción completa

Detalles Bibliográficos
Autores principales: Plüß, Marlene, Piantoni, Silvia, Tampe, Björn, Kim, Alfred H. J., Korsten, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359396/
https://www.ncbi.nlm.nih.gov/pubmed/35588699
http://dx.doi.org/10.1080/21645515.2022.2072143
_version_ 1784764132884480000
author Plüß, Marlene
Piantoni, Silvia
Tampe, Björn
Kim, Alfred H. J.
Korsten, Peter
author_facet Plüß, Marlene
Piantoni, Silvia
Tampe, Björn
Kim, Alfred H. J.
Korsten, Peter
author_sort Plüß, Marlene
collection PubMed
description In recent years, advances in the treatment and management of patients with systemic lupus erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus nephritis (LN) still represents a major life-threatening complication of the disease. Belimumab (BEL), a fully human monoclonal IgG1λ antibody neutralizing soluble B cell activating factor, was approved more than ten years ago as add-on therapy in adults and pediatric patients with a highly active, autoantibody-positive disease despite standard of care (SoC). Recently, the superiority of the addition of BEL to SoC was also demonstrated in LN. In this review, we provide a comprehensive overview of the study landscape, available therapeutic options for SLE (focusing on BEL in renal and non-renal SLE), and new perspectives in the treatment field of this disease. A personalized treatment approach will likely become available with the advent of novel therapeutic agents for SLE and LN.
format Online
Article
Text
id pubmed-9359396
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-93593962022-08-10 Belimumab for systemic lupus erythematosus – Focus on lupus nephritis Plüß, Marlene Piantoni, Silvia Tampe, Björn Kim, Alfred H. J. Korsten, Peter Hum Vaccin Immunother Immunotherapeutics – Product Review In recent years, advances in the treatment and management of patients with systemic lupus erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus nephritis (LN) still represents a major life-threatening complication of the disease. Belimumab (BEL), a fully human monoclonal IgG1λ antibody neutralizing soluble B cell activating factor, was approved more than ten years ago as add-on therapy in adults and pediatric patients with a highly active, autoantibody-positive disease despite standard of care (SoC). Recently, the superiority of the addition of BEL to SoC was also demonstrated in LN. In this review, we provide a comprehensive overview of the study landscape, available therapeutic options for SLE (focusing on BEL in renal and non-renal SLE), and new perspectives in the treatment field of this disease. A personalized treatment approach will likely become available with the advent of novel therapeutic agents for SLE and LN. Taylor & Francis 2022-05-19 /pmc/articles/PMC9359396/ /pubmed/35588699 http://dx.doi.org/10.1080/21645515.2022.2072143 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Immunotherapeutics – Product Review
Plüß, Marlene
Piantoni, Silvia
Tampe, Björn
Kim, Alfred H. J.
Korsten, Peter
Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
title Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
title_full Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
title_fullStr Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
title_full_unstemmed Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
title_short Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
title_sort belimumab for systemic lupus erythematosus – focus on lupus nephritis
topic Immunotherapeutics – Product Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359396/
https://www.ncbi.nlm.nih.gov/pubmed/35588699
http://dx.doi.org/10.1080/21645515.2022.2072143
work_keys_str_mv AT plußmarlene belimumabforsystemiclupuserythematosusfocusonlupusnephritis
AT piantonisilvia belimumabforsystemiclupuserythematosusfocusonlupusnephritis
AT tampebjorn belimumabforsystemiclupuserythematosusfocusonlupusnephritis
AT kimalfredhj belimumabforsystemiclupuserythematosusfocusonlupusnephritis
AT korstenpeter belimumabforsystemiclupuserythematosusfocusonlupusnephritis